Startups
Scala Biodesign’s software platform enables one-shot protein optimization by enhancing expression and stability, improving enzyme activity and optimizing therapeutic antibodies.
Overview
Location
Israel, Tel Aviv District, Tel Aviv
Total raised
$5.5M
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 11, 2023 | Scala Biodesign Raises USD5.5M in Seed Funding | Dr. Ravit Netzer (CEO) and Dr. Adi Goldenzweig (CTO) Credit: Omer Hacohen Scala Biodesign, a Tel Aviv, Israel-based biotechnology company which specializes in proteins development, raised USD$5.5M in Seed funding. The round was led by TLV P... |
| Sep 11, 2023 | Scala Biodesign launches with $5.5M to develop bioproducts from proteins | Photo: Yuichiro Chino /Heimsmyndir/Getty Images |
| Sep 11, 2023 | Scala Biodesign makes it easy to re-engineer proteins one molecule at a time – or 50 | There’s a gold rush on in biotech as AI and other tools are used to find new drugs and treatments. With $5.5 million in new funding, Scala Biodesign is focusing these methods on a related problem: making existing or promising drugs more pra... |
| Scala Biodesign | “Scala Biodesign’s software platform enables one-shot protein optimization by enhancing expression and stability, improving enzyme activity and optimizing therapeutic antibodies.” |
Reviews 0
FAQ about Scala Biodesign
How much funding has Scala Biodesign raised?
Scala Biodesign has raised $5.5M in total across 1 funding round.
What has the press written about Scala Biodesign?
Parsers VC has collected 5 articles mentioning Scala Biodesign, among them “Scala Biodesign Raises USD5.5M in Seed Funding” (Sep 11, 2023) and “Scala Biodesign launches with $5.5M to develop bioproducts from proteins” (Sep 11, 2023).
Is Scala Biodesign still active?
Yes, Scala Biodesign is active; its latest activity on Parsers VC dates from Mar 31, 2026.